Skip to content
Subscriber Only

Dr. Reddy’s Expanding Injectable Drug Offerings, Seeking Deals

Updated on

Dr. Reddy’s Laboratories Ltd. is expanding its U.S. offerings from basic generic pills to higher-end products like generic injectable drugs and could make acquisitions of as much $1 billion as it seeks to boost growth.

India’s second-largest drugmaker aims to file applications for four or five complex injectables for the U.S. market in the next 24 to 30 months, Chief Operating Officer Abhijit Mukherjee said in an interview.